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Ethical Acceptability of Postrandomization Consent
in Pragmatic Clinical Trials
David Gibbes Miller, MSc; Scott Y. H. Kim, MD, PhD; Xiaobai Li, PhD; Neal W. Dickert, MD, PhD; James Flory, MD, MSCE; Carlisle P. Runge, MS; Clare Relton, PhD
Abstract
IMPORTANCE Pragmatic clinical trials that seek informed consent after randomization (ie,
postrandomization consent) are increasingly used, but debate on ethics persists because control arm
patients are not specifically informed about the trials and randomization occurs before consent for
the trials. The public’s attitude toward postrandomization consent trials is unknown, but the way the
trials are described could bias people’s views.
OBJECTIVES To assess the attitudes of the US general public toward postrandomization informed
consent for pragmatic trials and tomeasure potential framing and other factors associatedwith those
attitudes.
DESIGN, SETTING, AND PARTICIPANTS An online, 2 × 2 experimental survey (fielded between
February 23 and April 3, 2018) portraying 4 scenarios of postrandomization informed consent (with
prior broad consent for medical record use) was conducted. These scenarios included traditional
randomized clinical trial language framing vs alternative framing in a high-stakes trial (ie, survival in
leukemia) or low-stakes trial (ie, blood glucose level in diabetes). A total of 3793 individuals invited to
participate were part of an existing panel representative of the US general public (GfK
KnowledgePanel).
MAINOUTCOMES ANDMEASURES The proportion of participants whowould recommend that an
ethics review board approve a postrandomization consent pragmatic trial.
RESULTS A total of 2042 of 3739 invitees (54.6%) responded; after exclusion of 38 incomplete
surveys, 2004 participants were included in the analysis. Of these, 997 (49.8%) were women, 1440
(71.9%) were white non-Hispanic, 199 (9.9%) were black non-Hispanic, and 233 (11.6%) were
Hispanic. Mean (SD) age was 47.5 (17.4) years. Across scenarios, weighted data showed that 75.4% of
the participants would recommend approval of the postrandomization consent pragmatic trial,
20.4%would probably not recommend approval, and 4.2%would definitely not recommend
approval. Approval was not sensitive to framing language (traditional vs new framing in high-stakes
scenario, 74.3% vs 76.8%, P = .40; in low-stakes scenario, 77.7% vs 72.9%, P = .10) or to the stakes
(low vs high stakes in traditional framing, 77.7% vs 74.3%, P = .25; in new framing, 72.9% vs 76.8%,
P = .18). Better understanding of the postrandomization consent designwas associatedwith higher
rate of approval (78.1% vs 65.0%, P = .002 for high-stakes scenario; 77.2% vs 64.9%, P = .004 for
low-stakes scenario), especially among those with less education. However, opinions about personal
involvement in the control armweremore cautious (range depending on scenario, 45.6%-59.7%)
and sensitive to stakes but not to framing.
CONCLUSIONS ANDRELEVANCE The public’s generally high rate of approval of the ethics of
postrandomization informed consent for pragmatic trial designs does not appear to be affected by
(continued)
Key Points
Question What are the opinions of the
general public on the ethics of pragmatic
trial designs in which specific informed
consent is obtained after randomization
from only the active arm of the trial?
Findings In this online survey study of
2004members of the US general public,
most participants (75.4%) would
recommend approval of the ethics of
the trial design, although personal
involvement in such trials had a lower
approval rate. Better understanding of
the postrandomization consent design
was associated with a higher rate of
approval.
Meaning Although controversial,
postrandomization consent for
pragmatic trials may be ethically
acceptable to the public, and education
may increase its acceptance.
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Abstract (continued)
whether postrandomization consent design is framed using traditional randomized clinical trial
terminology, regardless of the stakes of the trial. Promoting better understanding of the designmay
increase its acceptance by the public.
JAMA Network Open. 2018;1(8):e186149. doi:10.1001/jamanetworkopen.2018.6149
Introduction
Pragmatic clinical trials are seen as essential to the ideal of a learning health care system that
integrates medical care and clinical research to continually generate improvements in care.1 Such
trials use inclusive criteria to broadly involve patients in health systems to produce generalizable,
low-cost data and often use existing medical records as the source of outcome data.2,3 For
nonblinded trials using usual care for the control arm, some propose obtaining consent after
randomization, an idea first proposed by Zelen.4Other researchers have since proposed
modifications to this idea,5-8 and such trials are gaining increasing use.9,10
In postrandomization consent (PRC) trials, eligible patients are randomized to either the control
arm or the intervention arm first, and then only the intervention armparticipants are approached for
informed consent for that trial. Those in the control arm continue their usual course of treatment
and are not contacted specifically about the trial, but their medical records are used as data.
Although the design features can vary,6,8,11 eligibility for a PRC trial can be restricted to those who
have already given broad permission for the use of their medical records in research (Figure).11 Since
in the United States this is a likely restriction,11 our study focused on such PRC designs.
Postrandomization consent trials are attractive for several reasons, as they facilitate
recruitment and retention of the control arm, reduce the need for resources (eg, intervention-
specific informed consent is obtained from only half of the sample), reduce decisional burden for
intervention arm patients (the decision is whether to accept an intervention, as in real-life settings),
and potentially reduce the likelihood of disappointment for control arm patients.8,10,11 However,
critics have argued that all patients in PRC trials, including those receiving standard treatments, are
research participants who ought to go through a standard informed consent process.12,13
Commentators have criticized, among other things, the lack of transparency for control arm
participants and the fact that a research procedure (randomization) occurs without prior consent.14,15
If PRC designs are to be widely used for pragmatic trials, it is vital to understand whether the
public would find PRC designs ethically acceptable. Anyone who belongs to a health care system
could be involved in these trials, and public trust and buy-in would be crucial to a learning health care
system that uses such designs. But describing the PRC design to assess reactions to it may be
Figure. Diagram of Postrandomization Consent Process
Experimental intervention
Control intervention
Consent to study Randomization
Traditional RCT consentA
Experimental intervention
Control intervention
Broad consent for use
 of medical records
Randomization
Postrandomization consent with prior broad consentB
Consent A, Traditional process for participation in randomized
clinical trials (RCTs). B, Process for postrandomization
consent after broad consent for use of
medical records.
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challenging. For example, what is the best way to describe the control arm in a PRC design study?
Traditional randomized clinical trial (RCT) language would say that those individuals are research
participants of an RCT who have been assigned to the control arm of an experiment.
Presenting a study as not obtaining informed consent for participation in the RCT from such
participants seems likely to bias respondents toward believing that the study is unethical. However,
one could emphasize that in a PRC design none of the experiences of persons in the control arm (ie,
nothing affecting their clinical care) are altered by the trial, and only their medical records are used
as data (for which they would have given broad permission). These individuals serve as a kind of
prospective observational cohort.11 Framing the study in this way runs the risk of biasing respondents
toward acceptance. Thus, any study attempting to measure the public’s views on the ethical
acceptability of PRC designs must take into account the potential outcome of how such designs are
presented.
The purpose of this survey was to assess the US general public’s attitudes toward PRC designs
(using PRC design that includes broad consent for medical record use prior to randomization)
(Figure), by testing whether using a framing language different from the traditional RCT language
affects the public’s views about the ethical acceptability of PRC. To increase the generalizability of our
findings, we also assessed whether attitudes varied by the perceived seriousness of the disease and
outcomes being studied in the PRC trials (ie, stakes). We also examined factors (comprehension of
PRC design elements and demographics) associated with the public’s attitudes toward PRC.
Methods
StudyDesign
We used a 2 × 2 experimental survey design, testing the outcome of 2 different ways of describing
postrandomization consent procedures (traditional RCT language framing vs new framingminimizing
RCT language and noting, for example, lack of alteration of the control samples’ clinical course) and
targeting disorders of differing stakes (low-stakes trial of short-term blood glucose level control in
diabetes; high-stakes trial of survival rate in leukemia) on the general public’s attitudes toward PRC
(eFigure and eAppendix 1 in the Supplement). This study was deemed exempt from federal research
regulations by the National Institutes of Health Office of Human Subjects Research Protection.
Setting and Participants
The survey was administered through the GfK KnowledgePanel, an online, probability-based panel
representative of the adult US population. GfK follows the American Association for Public Opinion
Research (AAPOR) standards for response rate reporting and our report follows the AAPOR survey
disclosure checklist (eAppendix 2 in the Supplement). The GfK KnowledgePanel has previously been
used for other surveys about informed consent for clinical research.16-18 Panel members are recruited
through address-based sampling covering all US households, including those unreachable through
random digit dialing or without internet access (internet and web-enabled devices are provided for
such panel members).19 The survey used GfK’s Omnibus service, which fieldsmultiple nonoverlapping
surveys to a single nationally representative panel. Recruitment occurred in 2waves between February
23 and April 3, 2018.
SurveyMeasures
We conducted 3 pretest surveys on Amazon’s Mechanical Turk platform to optimize comprehension
of the 4 (2 framings ×2 stakes) scenarios by soliciting open-ended feedback. The surveywasmodified
in response to feedback from the Empirical Research Laboratory of the National Institutes of Health
Clinical Center’s Department of Bioethics. The instrument was finalized after the last round of
pretesting, which yielded correct answer rates ranging from 86% to 89% on the 3 comprehension
questions. The participants were randomized into 1 of 4 scenarios, but all were told to assume that
patients had provided prior broad consent for their medical records to be used in future research.
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The traditional framing used typical RCT language (eg, participating in an RCT, experimental
arm, and control arm) and a diagram showing randomization of eligible persons to 2 arms. The new
framing did not use these traditional terms and instead showed some persons being randomly
selected to be offered an experimental drug and the rest as continuing to receive usual care
(eAppendix 1 in the Supplement).
In all 4 scenarios, the experimental intervention was described as a “commonly available
nutritional supplement called MZN” that was being used as an add-on intervention to usual
treatments. For the high-stakes leukemia scenario, the primary outcomewas whether the drug
“prolongs the lives of patients with leukemia.” For the low-stakes scenario, the primary outcomewas
whether MZN “lowers blood sugar more than usual care alone.”
Participants in all groups were told that an ethics review board was reviewing the proposed
study to decide whether to approve it. The participants were first asked 3 knowledge questions to
assess understanding of the PRC trial design and the consent process. They were then asked 3
opinion questions regarding their attitudes toward postrandomization consent: a societal
perspective question about ethical acceptability (“Would you recommend to the ethics review board
that they approve this study?” ie, recommendation to ethics review board question) and 2 questions
from a personal perspective (“If you had diabetes and were assigned to the control group, it would
mean you would not be told about theMZN study specifically. Would that be okay with you?” and “If
you had diabetes andwere one of the patients eligible for theMZN clinical trial, howwould you feel
about being randomized to 1 of the 2 groups before anyone talked with you?”). The participants were
asked to provide written comments explaining their answers to the opinion questions; a separate
analysis and report are planned. The wording of questions, whenever necessary, was made
consistent with the scenario that the participant received. Participants were also asked to rate, on a
7-point scale, the risk level of the study proposal. GfK provided demographic information for all
participants.
Statistical Analysis
Sample size was calculated to allow us to detect an 8% difference in new and traditional framing
groups’ recommendations to the ethics review board in the high-stakes scenario (assuming
responses of 70% [traditional RCT framing] vs 78% [new framing]), with at least 80% power and a
2-sided α level of .05 using a χ2 test.
For analysis, we collapsed responses to all 3 opinion questions into dichotomous responses (eg,
an overall response of yes included both probably yes and definitely yes). All analyses, unless
otherwise specified, were conducted using survey weights provided by GfK, which accounted for our
sample having higher educational level attainment and household income than the general
population, as well as overrepresentation of persons older than 60 years and underrepresentation of
black and Hispanic persons. All tests were 2 sided, with statistical significance defined as P < .05.
Weighted proportions are reported only as percentages; unweighted proportions are reported with
the number and percentages.
The primary outcome of interest was the effect of framing on the participants’
recommendations to the review board to approve or not approve the study in the high-stakes
scenario; we reasoned that if a framing effect exists, it should bemost detectable in such a scenario.
Prespecified secondary analyses included the effect of framing on participants’ comfort with being
in the control group and not knowing about the study, the effect of framing on participants’ personal
acceptance (“okay”) with being randomized without being informed, the effect of stakes of the
scenarios on all 3 opinion questions, and the association between knowledge question responses
(using a knowledge score based on whether participants answered either 0-1 or 2-3 knowledge
questions correctly) and demographics with participants’ recommendations to the ethics
review board.
We used a χ2 test for all analyses except those involving risk level score (1-way analysis of
variance of mean scores of 4 groups) and demographics. The association between demographic
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factors (age, sex, race/ethnicity, educational level, and income) and recommendations to the review
board for the entire sample (all 4 arms combined)was examined using univariate logistic regression
models. For demographic variables showing a significant association (P < .05) with the
recommendation to the review board, we evaluated the effects of each covariate (with an additional
covariate of the participants’ knowledge score) inmultivariate logistic regressionmodels. All analyses
were conducted using SAS, version 9.4 (SAS Institute Inc).
Results
Participants
The survey was distributed to 3739 panelists, and 2042 individuals (54.6%) responded. Thirty-eight
surveys that did not have responses tomore than one-third of the questions were removed by GfK,
leaving a total sample of 2004 participants (53.6% of surveys sent). Of the respondents, 997
(49.8%) were women, themean (SD) age was 47.5 (17.4) years, 1440 (71.9%) were non-Hispanic
white, 199 (9.9%) were non-Hispanic black, 233 (11.6%) were Hispanic, and 723 (36.1%) were college
or higher graduates (unweighted demographics, Table 1).
Table 1. Unweighted Participant Characteristics
Characteristic
No. (%)
Overall
(N = 2004)
High-Stakes Leukemia Scenario Low-Stakes Diabetes Scenario
Traditional Framing
(n = 505)
New Framing
(n = 503)
Traditional Framing
(n = 498)
New Framing
(n = 498)
Sex
Male 1007 (50.2) 236 (46.7) 260 (51.7) 260 (52.2) 251 (50.4)
Female 997 (49.8) 269 (53.3) 243 (48.3) 238 (47.8) 247 (49.6)
Age, y
18-29 285 (14.2) 66 (13.1) 67 (13.3) 77 (15.5) 75 (15.1)
30-44 429 (21.4) 108 (21.4) 101 (20.1) 114 (22.9) 106 (21.3)
45-59 581 (29.0) 150 (29.7) 153 (30.4) 132 (26.5) 146 (29.3)
≥60 709 (35.4) 181 (35.8) 182 (36.2) 175 (35.1) 171 (34.3)
Race/ethnicity
White,
non-Hispanic
1440 (71.9) 362 (71.7) 357 (71.0) 372 (74.7) 349 (70.1)
Black,
non-Hispanic
199 (9.9) 53 (10.5) 55 (10.9) 44 (8.8) 47 (9.4)
Other,
non-Hispanic
81 (4.0) 19 (3.8) 20 (4.0) 23 (4.6) 19 (3.8)
Hispanic 233 (11.6) 57 (11.3) 60 (11.9) 54 (10.8) 62 (12.4)
≥2 Races,
non-Hispanic
51 (2.5) 14 (2.8) 11 (2.2) 5 (1.0) 21 (4.2)
Education
Less than high
school
165 (8.2) 36 (7.1) 34 (6.8) 40 (8.0) 55 (11.0)
High school 526 (26.2) 139 (27.5) 133 (26.4) 125 (25.1) 129 (25.9)
Some college 590 (29.4) 156 (30.9) 154 (30.6) 133 (26.7) 147 (29.5)
College graduate
or higher
723 (36.1) 174 (34.5) 182 (36.2) 200 (40.2) 167 (33.5)
Household income, $
<25 000 268 (13.4) 68 (13.5) 51 (10.1) 70 (14.1) 79 (15.9)
25 000-<50 000 382 (19.1) 97 (19.2) 111 (22.1) 83 (16.7) 91 (18.3)
50 000-<75 000 333 (16.6) 84 (16.6) 82 (16.3) 83 (16.7) 84 (16.9)
75 000-<100 000 287 (14.3) 76 (15.0) 74 (14.7) 68 (13.7) 69 (13.9)
100 000-<125 000 252 (12.6) 57 (11.3) 67 (13.3) 60 (12.0) 68 (13.7)
125 000-<150 000 134 (6.7) 38 (7.5) 36 (7.2) 30 (6.0) 30 (6.0)
≥150 000 348 (17.4) 85 (16.8) 82 (16.3) 104 (20.9) 77 (15.5)
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Overall Attitudes Toward Postrandomization Consent Trials
The overall proportion of participants who would definitely or probably recommend that the ethics
review board approve the study proposal was 75.4%, while 20.4%would probably not recommend
approval, and 4.2%would definitely not recommend approval. For questions from a personal
perspective, 53.2% of participants overall responded that they would be okay with being assigned to
the control group in the study proposal and not being told about the study specifically. A total of
59.8% of participants overall responded that they would be okay with being a patient eligible for the
study and being randomized to either the control group or the experimental group before anyone
talked to them about the study. There was no significant difference in mean risk perception scores
across the 4 groups (F3,1987 = 1.54, P = .20).
Effect of Framing
Although we hypothesized that there would be a framing effect on participants’ recommendations
to the ethics review board for the high-stakes leukemia trial scenario, no significant effect was seen:
76.8% in the new framing group would probably/definitely recommend approval vs 74.3% in the
traditional framing group (P = .40) (Table 2). There was also no significant framing effect in the
low-stakes diabetes trial scenario (72.9%would recommend approval in new framing vs 77.7% in
traditional framing, P = .10).
Regarding whether participants would be okay with being assigned to the control group
without being told about the study, there was no significant difference between traditional and new
framing in the high-stakes group (49.2% vs 45.6%, P = .27) or in the low-stakes group (58.4% vs
59.7%, P = .68). Most participants also stated they would be okay with being randomized without
being informed, but this response was subject to a small framing effect that was significant in the
high-stakes scenario (52.1% traditional framing vs 59.8% new framing, P = .02) andmarginal in the
low-stakes scenario (60.6% in traditional framing vs 66.8% in new framing, P = .05).
Effect of Stakes
The stakes of the study proposal had no effect on whether participants would recommend that the
ethics review board approve the study (77.7% in the low-stakes scenario vs 74.3% in the high-stakes
scenario, P = .25 for traditional framing; 72.9% in the low-stakes scenario vs 76.8% in the high-
stakes scenario, P = .18 for new framing).
The stakes of the study proposal had a significant effect for both questions about personal
involvement. The proportion of participants responding that they would be okay with being in the
Table 2. Effect of Framing and Stakes on Recommendation to Ethics Review Board and Personal Preferences
Response
Weighted % χ2 Test (P Value)b
Overall
(N = 2004)a
High-Stakes Leukemia Scenario Low-Stakes Diabetes Scenario Framing Effect Stakes Effect
1 Traditional Framing
(n = 505)
2 New Framing
(n = 503)
3 Traditional Framing
(n = 498)
4 New Framing
(n = 498) 1 vs 2 3 vs 4 1 vs 3 2 vs 4
Probably or
definitely
recommend the
review board
approve the study
75.4 74.3 76.8 77.7 72.9 0.85
(.40)
3.01
(.10)
1.53 (.25) 2.03 (.18)
Probably or
definitely okay with
being assigned to
control group and
not being told about
study
53.2 49.2 45.6 58.4 59.7 1.34
(.27)
0.19
(.68)
8.39 (.006) 20.10
(<.001)
Probably or
definitely okay with
being randomized
without being
informed
59.8 52.1 59.8 60.6 66.8 6.01
(.02)
4.10
(.05)
7.32 (.01) 5.26 (.03)
a Each test excluded cases that did not respond to the corresponding question. b All tests used 1 df. All analyses were weighted.
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control group and not being told about the study was 58.4% in the low-stakes and 49.2% in the high-
stakes scenarios (P = .006) with traditional framing and 59.7% in the low-stakes and 45.6% in the
high-stakes scenarios (P < .001) with new framing. The proportion of participants whowould be okay
with being randomized for the study without being informedwas 60.6% in the low-stakes vs 52.1%
in the high-stakes scenarios (P = .01) for traditional framing and 66.8% vs 59.8% for new framing
(P = .03).
AssociationWith Knowledge Scores
Overall, 1701 participants (86.4%) answered 2 or more knowledge questions correctly (703 [35.7%]
answered 2 questions correctly and 998 [50.7%] answered all 3 questions correctly). Therewas no
significant difference in the number of knowledge questions answered correctly between the high-
and low-stakes scenario groups (86.8% high stakes vs 85.3% low stakes, P = .34) or between the
traditional and new framing groups (85.2% vs 86.9%, P = .30).
Answering 2 or more knowledge questions correctly was associated with increased acceptance
of the PRC study design. In both the high- and low-stakes groups, those who understood the study
proposal were more likely to recommend that the ethics review board approve the study (77.2% vs
64.9%, P = .004 in low-stakes and 78.1% vs 65.0%, P = .002 in high-stakes scenarios) (Table 3). This
association was also seen among those whowere okay with being in the control group of the study
and not being told about the study (61.7% vs 41.6%, P < .001 in low-stakes and 49.5% vs 39.5%,
P = .04 in high-stakes scenarios), and among those whowere okay with being randomized without
being informed (67.1% vs 44.6%, P < .001 in low-stakes and 58.8% vs 43.2%, P = .001 in high-stakes
scenarios).
Demographic Factors and Recommendation to Ethics ReviewBoard
In unadjusted analysis, race/ethnicity, educational level, and income, but not age and sex, were
significantly associated with participants’ recommendations to the ethics review board (Table 4).
Black participants were less likely than white, non-Hispanic participants to recommend that the
review board approve the study. Amultivariate logistic model with all significant covariates showed
that only educational level (less than high school as reference: high school graduate, odds ratio [OR],
1.62; 95% CI, 1.08-2.43; some college, OR, 1.50; 95% CI, 1.00-2.25; college graduate or higher, OR,
1.82; 95% CI, 1.18-2.80) and knowledge score (2 correct vs not, OR, 1.80; 95% CI, 1.34-2.41) had
significant independent associations. In a model with educational level (dichotomized as less than
high school vs high school graduate or higher, because of similar ORs in the abovemodel), knowledge
score, and a term for interaction of the 2models, we found a significant interaction between
knowledge score and educational level such that the associations with knowledge score in the lowest
educational level group (less than a high school education) were greater than in thosewithmore than
a high school education (OR, 6.69; 95% CI, 2.49-17.96 vs OR, 1.56; 95% CI, 1.13-2.14; P = .006).
Table 3. Association Between Knowledge Question Responses and Recommendation to Ethics Review Board and Personal Preferences
Response
Knowledge Questions Correct, %a
Overall (N = 2004) High-Stakes Leukemia Scenario (n = 1008)b Low-Stakes Diabetes Scenario (n = 996)b
0-1
(n = 268)
2-3
(n = 1701)
0-1
(n = 139)
2-3
(n = 851) χ2 (P Value)c
0-1
(n = 129)
2-3
(n = 850) χ2 (P Value)c
Recommends that the review board approve
the study
65.0 77.6 65.0 78.1 11.55 (.002) 64.9 77.2 9.08 (.004)
Okay with being assigned to control group
and not being told about study
40.5 55.6 39.5 49.5 4.85 (.04) 41.6 61.7 18.46 (<.001)
Okay with being randomized without being
informed
43.8 62.9 43.2 58.8 12.12 (.001) 44.6 67.1 23.90 (<.001)
a Each test excluded cases that did not respond to the corresponding questions. The 35
cases that did not include a response to at least 1 knowledge question were excluded
(18 questions in high-stakes groups and 17 in low-stakes groups).
b Both new and traditional framing groups were collapsed into a single group for this
analysis.
c All tests used 1 df. All analyses were weighted.
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Discussion
Although pragmatic RCTs using PRC have potential advantages, commentators continue to debate
the ethical acceptability of the lack of specific consent from the control group and of randomization
(a research procedure) before consent for such RCTs.11,12When ethical intuition is divided in a policy
area that requires the support of the public (as pragmatic trials must be), it is important to
understand the public’s stance regarding the ethics of these issues.
Our primary outcome (framing association in the high-stakes scenario) was based on the
concern that the language of traditional RCTs, if used to describe elements of PRC designs, could lead
respondents to not recognize important ethical features of PRC studies.We found, however, that the
participants’ recommendations to an ethics review board were not affected by how the PRCwas
described. In light of this information, it appears that the concern over the influence of languagemay
loom large for ethicists and institutional review boardmembers who are immersed in the ethics
debates but that the public are able to focus on design elements of PRC trials without being
influenced by the language.
Table 4. Association Between Demographics and Knowledge ScoresWith Recommendation to Review Board
for All 4 Groupsa
Characteristic
Overall Unweighted
n = 2004), No. (%)
Recommending
Approval, Weighted % χ2 (P Value)b
Sex
Male 1007 (50.2) 75.3
0.016 (.91)
Female 997 (49.8) 75.5
Income category, $
<25 000 268 (13.4) 66.4
21.40 (.004)
25 000-<50 000 382 (19.1) 73.0
50 000-<75 000 333 (16.6) 77.6
75 000-<100 000 287 (14.3) 79.8
100 000-<125 000 252 (12.6) 77.9
125 000-<150 000 134 (6.7) 81.5
≥150 000 348 (17.4) 76.6
Education level
<High school 165 (8.2) 63.3
23.05 (<.001)
High school graduate 526 (26.2) 75.0
Some college 590 (29.4) 75.5
≥College graduate 723 (36.1) 79.8
Race/ethnicity
White, non-Hispanic 1440 (71.9) 77.9
14.77 (.03)
Black, non-Hispanic 199 (9.9) 67.3
Other, Non-Hispanic 81 (4.0) 72.8
Hispanic 233 (11.6) 72.0
≥2 Races, non-Hispanic 51 (2.5) 76.5
Age, y
18-24 184 (9.2) 68.8
10.08 (.17)
25-34 401 (20.0) 72.0
35-44 329 (16.4) 78.1
45-54 316 (15.8) 76.2
55-64 396 (19.8) 78.0
65-74 259 (12.9) 76.0
≥75 119 (5.9) 77.7
Knowledge questions correct
0-1 268 (13.6) 65.0
20.53 (<.001)
2-3 1701 (86.4) 77.6
a Incomplete responses in 35 participants.
b χ2 Test between demographic category and
percentage recommending approval.
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This study yielded several additional findings. First, there was significant support generally for
postrandomization consent in pragmatic trials, with 75.4% of participants recommending that the
ethics review board approve the study and 4.2% of people saying they would definitely not
recommend approval.
Second, the questions about personal involvement in the trial yielded lower—but still more than
half—approval rates (53.2% for being in the control group without being told about the study and
59.8% for being randomized without being informed). We do not think this discrepancy between
perspectives taken is irrational (eg, onemight find research studies ethically acceptable but may not
personally wish to participate, indicating thatmany peoplemay find lack of full transparency involved
in the control arm of PRC trials personally unacceptable). The results echo a previous finding that,
although 68% of US adults are willing to provide open-ended consent for research with donated
tissues, fewer are willing when told about potential uses under such open-ended consent (eg, 55%
for use in commercial drug development).17However, these respondents’ preferred solution was not
specific consent for each research use but some form of enhanced broad consent, such as broad
consent with a general caution (eg, some people might havemoral, religious, or cultural concerns
about some uses) or broad consent with easy access to a list of research projects with the option to
withdraw.17
Third, most people understood (answered 2-3 knowledge questions correctly) the key design
elements of the described PRC trials and they were significantly more likely to approve of a PRC
design than those with poor comprehension. This association was not fully explained by any
demographic variable, including educational level. The interaction (this knowledge association was
most pronounced in the lowest educational level group) also highlights the importance of
comprehending the rather complex design of PRC studies. Overall, the results suggest that public
education will help improve acceptance of PRC in pragmatic trials.
Limitations
There are several limitations to this study. First, this survey used hypothetical scenarios, asking
participants to play roles with which theymay not be familiar (albeit as a tool for gauging their
intuition on ethics). Second, this study tested a type of PRC design that requires broad permission for
the use of patients’ medical records—a feature that is not shared by all PRC designs.5,6 Third,
although a 55% response rate is good for an online public survey, we had to use weighted analyses to
optimize generalizability. Fourth, the RCT scenarios portrayed a commonly used food supplement
as the intervention, whichmay not generalize to scenarios of riskier interventions. We can only
speculate on how a riskier interventionmight affect attitudes since such an intervention that would
be reasonable to test should also have at least a perceived higher potential for benefit.
Conclusions
As pragmatic clinical trials using novel consent designs becomemore common, understanding the
public’s attitudes toward the ethical dimensions of such trials may help researchers design and
institutional review boards evaluate PRC protocols in a more informedmanner. We found a generally
high rate of acceptability regarding the ethics of PRC trials that was not sensitive to whether
traditional RCT language is used. Still, the high level of approval must be interpreted in light of a
lower, but still relatively high, level of comfort in situations with more affective salience for the
participants (ie, when they are asked to imagine themselves in the PRC trials), especially in higher-
stakes trials. A key finding was that participants who better understood PRC design were more likely
to approve of the PRC study, indicating the importance of educating people about such designs. As
pragmatic trials grow in popularity, greater public education may be an important step to ensuring
transparency, trust, and acceptance of the clinical research enterprise in general and the PRC designs
in particular.
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